Myeloid-derived suppressor sells and the efficacy of CD8+ T-cell immunotherapy Journal Article

   


Authors: Lesokhin, A. M.; Merghoub, T.; Wolchok, J. D.
Article Title: Myeloid-derived suppressor sells and the efficacy of CD8+ T-cell immunotherapy
Abstract: Myeloid-derived suppressor cells (MDSCs) promote immune evasion, a key feature of oncogenesis. The restoration of immunosurveillance by immunomodulatory antibodies improves the survival of a subset of cancer patients. Preclinical studies suggest that the ablation of monocytic MDSCs may be a useful adjunct to available immunotherapeutic strategies against cancer. © 2013 Landes Bioscience.
Keywords: cancer survival; treatment outcome; overall survival; nonhuman; note; cd8+ t lymphocyte; cell proliferation; ipilimumab; cancer immunotherapy; melanoma; granulocyte macrophage colony stimulating factor; carcinogenesis; immunotherapy; cd11b antigen; immunomodulation; clinical effectiveness; immunosuppressive treatment; immunosurveillance; cell expansion; chemokine receptor ccr2; monocyte chemotactic protein 1; suppressor cell; gm-csf; immune evasion; tumor ablation; nitrosylation; tumor escape; ccr2; myeloid derived suppressor cells; adoptive t-cell transfer; monocytic myeloid derived suppressor cell
Journal Title: OncoImmunology
Volume: 2
Issue: 2
ISSN: 2162-4011
Publisher: Landes Bioscience  
Date Published: 2013-02-01
Start Page: e22764
Language: English
DOI: 10.4161/onci.22764
PROVIDER: scopus
PMCID: PMC3601158
PUBMED: 23525353
DOI/URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-84886945666&partnerID=40&md5=5eadc8da961e0f97a472807b9e907e8b
Notes: --- - "Export Date: 2 December 2013" - "Source: Scopus"
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Jedd D Wolchok
    905 Wolchok
  2. Taha Merghoub
    364 Merghoub
  3. Alexander Meyer Lesokhin
    363 Lesokhin
Related MSK Work